Stocksigma LogoStocksigma Logo

Balaxi Pharmaceuticals Ltd - Financial Result for the Quarter ended 30th Sep'26 (Consolidated, INR Lakh)

■ Revenue: 8,137 (+44.9% YoY | +0.9% QoQ) ■ EBITDA: 512 (+338.0% YoY | +9.8% QoQ) ■ EBITDA Margin (%): 6.3 (+421 bps YoY | +51 bps QoQ) ■ PAT: 115 (+450.3%

Balaxi Pharmaceuticals Ltd - Financial Result for the Quarter ended 30th Sep'26 (Consolidated, INR Lakh)

Balaxi Pharmaceuticals Ltd · Outcome · 12 Nov 2026, 7:28 pm

Balaxi Pharmaceuticals Ltd - Financial Result for the Quarter ended 30th Sep'26 (Consolidated, INR Lakh) ■ Revenue: 8,137 (+44.9% YoY | +0.9% QoQ) ■ EBITDA: 512 (+338.0% YoY | +9.8% QoQ) ■ EBITDA Margin (%): 6.3 (+421 bps YoY | +51 bps QoQ) ■ PAT: 115 (+450.3% YoY | -11.3% QoQ) ■ EPS (INR): 0.21 (+425.0% YoY | -12.5% QoQ)

Original exchange filing (PDF)

More announcements from Balaxi Pharmaceuticals Ltd

All Balaxi Pharmaceuticals Ltd announcements